<?xml version="1.0" encoding="UTF-8"?>
<p>SARS-CoVs replication also requires other enzymatic activities including (guanine-N7)-methyltransferase (N7-MTase), 2’-O-methyltransferase (2’-OMTase) and exoribonuclease (ExoN).
 <xref rid="B57" ref-type="bibr">
  <sup>57</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B107" ref-type="bibr">
  <sup>107</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B108" ref-type="bibr">
  <sup>108</sup>
 </xref> The N7-MTase domain at the C-terminus of Nsp14 is responsible for adding a methyl group in the N7 position of RNA 5’-guanosine forming the 5’-cap structure of viral RNAs.
 <xref rid="B108" ref-type="bibr">
  <sup>108</sup>
 </xref> Additionally, Nsp14 also has a catalytic domain in its N-terminus with 3’-5’ ExoN activity, which participates in RNA proofreading mechanism (
 <xref ref-type="fig" rid="f8">Fig. 8</xref>).
 <xref rid="B57" ref-type="bibr">
  <sup>57</sup>
 </xref> 2’-OMTase (Nsp16) catalyses the methylation reaction at the ribose 2’-O position of the first and second nucleotide of the mRNAs and it is one of the SARS-CoV-2 proteins whose 3D structure has already been resolved (PDB: 6W61, 2.0 Å) (
 <xref ref-type="fig" rid="f9">Fig. 9</xref>).
 <xref rid="B109" ref-type="bibr">
  <sup>109</sup>
 </xref> Both Nsp14 and 16 use Nsp10 as a cofactor to enhance their 3’-5’ ExoN and 2’-OMTase activities, respectively.
 <xref rid="B110" ref-type="bibr">
  <sup>110</sup>
 </xref> Together, these proteins are responsible for inducing RNA modifications that are essential for its stability and translation as well to avoid the activation of host immune response.
 <xref rid="B57" ref-type="bibr">
  <sup>57</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B107" ref-type="bibr">
  <sup>107</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B109" ref-type="bibr">
  <sup>109</sup>
 </xref> Thus, Nsp14 and 16 have been considered as potential targets for anti-SARS agents that may affect their functions in a direct or indirect way (e.g., by blocking Nsp 10 binding).
 <xref rid="B108" ref-type="bibr">
  <sup>108</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B109" ref-type="bibr">
  <sup>109</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B110" ref-type="bibr">
  <sup>110</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B111" ref-type="bibr">
  <sup>111</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B112" ref-type="bibr">
  <sup>112</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B113" ref-type="bibr">
  <sup>113</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B114" ref-type="bibr">
  <sup>114</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B115" ref-type="bibr">
  <sup>115</sup>
 </xref> Some compounds have been regarded as potential inhibitors of SARS-CoV-2 methyl transferases, such as adenine dinucleoside S-adenosylmethionine analogs [e.g., dinucleoside 13 (15)], predicted for SARS-CoV N7-MTase activity, and some clinically available drugs [e.g., raltegravir (16) - a HIV integrase inhibitor], predicted for SARS-CoV-2 2’-OMTase activity.
 <xref rid="B112" ref-type="bibr">
  <sup>112</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B115" ref-type="bibr">
  <sup>115</sup>
 </xref> Chemical structures for compounds 15-29 are shown in 
 <xref ref-type="fig" rid="f10">Fig. 10</xref>.
</p>
